Many young U.S. men at high risk for HIV do not take anti-HIV pill

By Natalie Grover (Reuters Health) - Less than 4 percent of young adult men-who-have-sex-with-men in the U.S. – a population at significant risk of contracting the human immunodeficiency virus (HIV) – reported ever using the pill that protects them from the virus, in a recently published study. “We have had a sense that PrEP is not reaching the communities that could benefit from it most, but the overall level of 3.4% is surprisingly low,” said Dr. Ryan Westergaard, an infectious disease physician at UW Health in Madison, Wisconsin, who was not involved in the study. Approved in the U.S. in 2012, the pill is marketed by Gilead Sciences Inc. under the brand name Truvada.